Status:
COMPLETED
A 6-Month Study Of CP-690,550 Versus Tacrolimus In Kidney Transplant Patients
Lead Sponsor:
Pfizer
Conditions:
Kidney Transplantation
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
This Phase 2 study was designed to evaluate the safety and efficacy of 2 dose levels of CP-690,550 (15 mg twice daily and 30 mg twice) against tacrolimus, in combination with basiliximab induction, my...
Eligibility Criteria
Inclusion
- Recipient of a first-time kidney transplant
- Between the ages of 18 and 70 years, inclusive
Exclusion
- Recipient of any non-kidney transplant
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2006
Estimated Enrollment :
61 Patients enrolled
Trial Details
Trial ID
NCT00106639
Start Date
May 1 2005
End Date
July 1 2006
Last Update
March 12 2013
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Los Angeles, California, United States, 90057
2
Pfizer Investigational Site
Los Angeles, California, United States, 92356
3
Pfizer Investigational Site
Palo Alto, California, United States, 94304
4
Pfizer Investigational Site
San Diego, California, United States, 92123